9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

W.E.E.Eberhardt; B.E.Johnson; Y.Sun; P.Germonpré; N.Saijo; C.Zhou; J.Wang; H.Tada; S.J.Kennedy; R.S.Herbst

首页> 外文期刊>European Journal of Cancer Supplements >9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

【24h】

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
W.E.E.Eberhardt; B.E.Johnson; Y.Sun; P.Germonpré; N.Saijo; C.Zhou; J.Wang; H.Tada; S.J.Kennedy; R.S.Herbst;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
2. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. [J] . Herbst RS, Sun Y, Eberhardt WE, The lancet oncology . 2010,第7期

机译：Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（ZODIAC）患者的二线治疗：一项双盲，随机，3期试验。
3. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. [J] . Farina G, Longo F, Martelli O, Clinical lung cancer . 2011,第2期

机译：治疗的理由和量身定制的研究设计：厄洛替尼与多西紫杉醇二线治疗不存在表皮生长因子受体突变的晚期非小细胞肺癌患者的三线随机试验。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind randomised phase 3 trial [O] . Prof Roy S Herbst, Yan Sun, Wilfried E E Eberhardt, -1

机译：凡德他尼加上多西他赛多西他赛与作为二线治疗患有晚期非小细胞肺癌（ZODIaC）：双盲随机化3期临床试验
7. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer [O] . J.V. Heymach, S.J. Lockwood, R.S. Herbst, 2014

机译：EGFR Biomarkers预测Vandetanib的益处与多西紫杉醇组合在随机的非小细胞肺癌患者的二线治疗的随机期III研究中

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

著录项

相似文献

相关主题

期刊订阅